Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed non-small cell lung cancer (NSCLC)
• * Meets 1 of the following stage criteria:
• * Completely resected stage I-IIIB disease
• * Underwent surgical resection \> 4 weeks but ≤ 4 years ago
• * Unresectable stage IIIA or IIIB disease AND previously treated with definitive radiotherapy or chemotherapy \> 6 weeks ago
• * Bronchoalveolar carcinomas allowed
• Clinically stable disease by chest x-ray or CT scan within the past 6 weeks
• * No progressive disease
• No malignant pleural or pericardial effusions
• PATIENT CHARACTERISTICS:
• Age
• 18 to 80
• Performance status
• ECOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Hemoglobin ≥ 9.0 g/dL
• Hepatic
• Bilirubin ≤ 2.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN
• No known history of infectious hepatitis
• Renal
• Creatinine ≤ 3 mg/dL
• Ionized calcium ≥ 0.9 mmol/L (may be replaced)
• Cardiovascular
• No known New York Heart Association class III-IV congestive heart failure
• No hemodynamically significant valvular heart disease
• No myocardial infarction within the past 6 months
• No active angina pectoris
• No uncontrolled ventricular arrhythmia
• No stroke within the past year
• No known cerebrovascular disease
• No other significant cardiac disease by echocardiogram, stress test, or risk assessment by cardiologist (for patients suspected of cardiac disease by history or physical exam)
• Immunologic
• No known HIV positivity
• No other immunosuppressive disorders, including chronic disorders
• Other
• Not pregnant
• Negative pregnancy test
• Potassium ≥ 3.0 mEq/L (may be replaced)
• Able to tolerate modest blood volume and electrolyte shifts during leukapheresis
• No other malignancy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Prior biologic therapy allowed
• Other concurrent biologic therapy allowed
• Chemotherapy
• See Disease Characteristics
• No concurrent chemotherapy
• Endocrine therapy
• No concurrent steroids during and for 16 weeks after study treatment
• Radiotherapy
• See Disease Characteristics
• No concurrent radiotherapy
• Surgery
• See Disease Characteristics
• Other
• Prior neoadjuvant or adjuvant therapy for surgically resected patients allowed
• No concurrent shorter courses of immunosuppressive medications during and for 16 weeks after study treatment
• No concurrent chronic immunosuppressive medications
• Concurrent cyclooxygenase-2 inhibitors allowed